Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
Abstract Background The HER2 extracellular domain shed in blood (HER2ECD) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2ECD values in patients with metastatic breast cancer treated in the SAKK22/99 trial c...
Sparad:
| Huvudupphov: | , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMC
2020-02-01
|
| Serie: | BMC Cancer |
| Ämnen: | |
| Länkar: | https://doi.org/10.1186/s12885-020-6594-0 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|